Overview

EPO906 Therapy in Patients With Prostate Cancer

Status:
Completed

Trial end date:
2004-01-01

Target enrollment:

Participant gender:

Summary

This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause prostate cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

Androgens
Epothilone B
Epothilones